These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 26839360)
1. A patient with complex multiple genomic ALK alterations. Liu X; Rice SJ; Jamis-Dow CA; Abendroth C; Ali S; Almokadem S; Belani CP Thorax; 2016 Apr; 71(4):383-5. PubMed ID: 26839360 [No Abstract] [Full Text] [Related]
2. Cystic Brain Metastases in NSCLC Harboring the EML4-ALK Translocation after Treatment with Crizotinib. Saraceni C; Li PM; Gainor JF; Stopyra GA; Friedman EL J Thorac Oncol; 2015 Jul; 10(7):1116-7. PubMed ID: 26134230 [No Abstract] [Full Text] [Related]
3. Surviving respiratory insufficiency with intensive care support in a pretreated, extensively metastasized patient with an EML4-ALK translocation. van Geffen WH; Hiltermann TJ; Groen HJ J Thorac Oncol; 2013 Jan; 8(1):e1-2. PubMed ID: 23242444 [No Abstract] [Full Text] [Related]
4. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer. Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691 [TBL] [Abstract][Full Text] [Related]
5. Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-targeted therapy for advanced non-small cell lung cancer: molecular and clinical aspects. Okamoto I; Nakagawa K Cancer Sci; 2012 Aug; 103(8):1391-6. PubMed ID: 22568572 [TBL] [Abstract][Full Text] [Related]
6. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene. Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107 [TBL] [Abstract][Full Text] [Related]
7. Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling. Le X; Freed JA; VanderLaan PA; Huberman MS; Rangachari D; Jorge SE; Lucena-Araujo AR; Kobayashi SS; Balasubramanian S; He J; Chudnovsky Y; Miller VA; Ali SM; Costa DB Clin Lung Cancer; 2015 Sep; 16(5):e105-9. PubMed ID: 25922291 [TBL] [Abstract][Full Text] [Related]
9. Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: case report. Campos-Gomez S; Lara-Guerra H; Routbort MJ; Lu X; Simon GR Int J Biol Markers; 2015 May; 30(2):e254-7. PubMed ID: 25588859 [TBL] [Abstract][Full Text] [Related]
10. Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing. Saber A; van der Wekken AJ; Kok K; Terpstra MM; Bosman LJ; Mastik MF; Timens W; Schuuring E; Hiltermann TJ; Groen HJ; van den Berg A PLoS One; 2016; 11(4):e0153065. PubMed ID: 27045755 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness of crizotinib in a patient with ALK IHC-positive/FISH-negative metastatic lung adenocarcinoma. Rosoux A; Pauwels P; Duplaquet F; D'Haene N; Weynand B; Delos M; Menon R; Heukamp LC; Thunnissen E; Ocak S Lung Cancer; 2016 Aug; 98():118-121. PubMed ID: 27393517 [TBL] [Abstract][Full Text] [Related]
12. Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: A new mechanism of resistance to ALK inhibitors. Levacq D; D'Haene N; de Wind R; Remmelink M; Berghmans T Lung Cancer; 2016 Dec; 102():38-41. PubMed ID: 27987586 [TBL] [Abstract][Full Text] [Related]
13. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative. Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132 [TBL] [Abstract][Full Text] [Related]
14. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity. Kimura H; Nakajima T; Takeuchi K; Soda M; Mano H; Iizasa T; Matsui Y; Yoshino M; Shingyoji M; Itakura M; Itami M; Ikebe D; Yokoi S; Kageyama H; Ohira M; Nakagawara A Lung Cancer; 2012 Jan; 75(1):66-72. PubMed ID: 21757253 [TBL] [Abstract][Full Text] [Related]
15. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance. Toyokawa G; Seto T Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376 [TBL] [Abstract][Full Text] [Related]
16. Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer. Tiseo M; Gelsomino F; Bartolotti M; Bordi P; Bersanelli M; Rossi G; Ardizzoni A Expert Rev Anticancer Ther; 2011 Nov; 11(11):1677-87. PubMed ID: 22050016 [TBL] [Abstract][Full Text] [Related]
17. In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line. Nanjo S; Nakagawa T; Takeuchi S; Kita K; Fukuda K; Nakada M; Uehara H; Nishihara H; Hara E; Uramoto H; Tanaka F; Yano S Cancer Sci; 2015 Mar; 106(3):244-52. PubMed ID: 25581823 [TBL] [Abstract][Full Text] [Related]
18. Clinical response to crizotinib retreatment after acquisition of drug resistance. Matsuoka H; Kurata T; Okamoto I; Kaneda H; Tanaka K; Nakagawa K J Clin Oncol; 2013 Jul; 31(19):e322-3. PubMed ID: 23715571 [No Abstract] [Full Text] [Related]
19. Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target. Demeure MJ; Aziz M; Rosenberg R; Gurley SD; Bussey KJ; Carpten JD World J Surg; 2014 Jun; 38(6):1296-305. PubMed ID: 24633422 [TBL] [Abstract][Full Text] [Related]
20. K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature. Mengoli MC; Barbieri F; Bertolini F; Tiseo M; Rossi G Lung Cancer; 2016 Mar; 93():55-8. PubMed ID: 26898615 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]